Table 1.
Patients’ characteristics.
| Total (N = 226) | STAS negative (n = 191) | STAS positive (n = 35) | p value |
|---|---|---|---|
| Age (y) (median, range) | 70 (39–88) | 68 (38–89) | 0.29 |
| Gender, male/female | 103 (54%)/88 (46%) | 20 (57%)/15 (43%) | 0.85 |
| Brinckmann index (median, range) | 300 (0–2760) | 500 (0–1600) | 0.33 |
| FEV1 (L) | 2.13 (0.95–4.11) | 2.08 (0.9–3.95) | 0.33 |
| FEV1 predicted (%) | 90.6 (45.9–140.5) | 90.2 (49.7–138.7) | 0.81 |
| Comorbidities | |||
| Chronic obstructive pulmonary disease | 69 (36%) | 14 (40%) | 0.71 |
| Cardiac disorder | 36 (19%) | 9 (26%) | 0.36 |
| Hypertension | 62 (32%) | 10 (29%) | 0.70 |
| Diabetes | 33 (17%) | 3 (9%) | 0.31 |
| Radiologic tumor diameter | 14.0 (5.6–2.0) | 14.2 (7.0–19.0) | 0.82 |
| C/T ratio ≦0.25/ > 0.25 | 40 (21%)/151 (79%) | 2 (6%)/33 (94%) | 0.03 |
| Surgical procedure | 0.28 | ||
| Lobectomy | 86 (45%) | 20 (57%) | |
| Segmentectomy | 70 (37%) | 8 (23%) | |
| Wedge resection | 35 (18%) | 7 (20%) | |
| Tumor histology | < 0.01 | ||
| Adenocarcinoma | 150 (79%) | 31 (89%) | |
| AIS, MIA/Lepidic/Papillary/Acinar/Solid/Micropapillary/Variant | 68 (45%)/12 (8%)/46 (31%)/10 (7%)/ 5 (3%)/0 (0%)/9 (6%) | 1 (3%)/0 (0%)/18 (58%)/4 (13%)/ 0 (0%)/4 (13%)/4 (13%) | < 0.001 |
| Squamous cell carcinoma | 34 (18%) | 1 (3%) | |
| Others | 7 (4%) | 3 (9%) | |
| Pathologic stage | |||
| T1a/T1b/T2/T3/T4 | 148 (77%)/11 (6%)/30 (16%)/2 (1%)/0(0%) | 22 (63%)/7 (20%)/6 (17%)/0 (0%)/0 (0%) | 0.07 |
| N0/N1/N2/N3/NX | 152 (79%)/1 (1%)/5 (3%)/0 (0%)/33 (17%) | 24 (69%)/5 (14%)/4 (11%)/0 (0%)/2 (6%) | < 0.001 |
| Stage IA/IB/II/III/IV | 156 (81%)/26 (14%)/4 (2%)/5 (3%)/0 (0%) | 22 (63%)/4 (11%)/5 (15%)/4 (11%)/0 (0%) | < 0.01 |
| Pathologic lymphatic invasion | 12 (6%) | 8 (23%) | < 0.01 |
| Pathologic vascular invasion | 34 (18%) | 11 (31%) | 0.07 |
| Pathologic plural invasion | 30 (16%) | 5 (14%) | 1.00 |
| EGFR Wildtype/Mutant | 8 (47%)/9 (53%) | 4 (40%)/6 (60%) | 1.00 |